{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:52Z","timestamp":1786119412142,"version":"build-2736575974"},"reference-count":144,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.3109\/10673221003747690","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T06:09:35Z","timestamp":1272262175000},"page":"158-172","source":"Crossref","is-referenced-by-count":24,"title":["The Elderly Safety Imperative and Antipsychotic Usage"],"prefix":"10.1097","volume":"18","author":[{"given":"Lama M.","family":"Chahine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diler","family":"Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Chemali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/YCO.0b013e3282f0f09d","article-title":"The many faces of psychosis in the elderly.","volume":"20","author":"Broadway","year":"2007","journal-title":"Curr Opin Psychiatry"},{"key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","article-title":"A history of antipsychotic drug development.","volume":"40","author":"Shen","year":"1999","journal-title":"Compr Psychiatry"},{"key":"R3-2-20210129","first-page":"225","article-title":"Are second generation antipsychotics a distinct class J Psychiatr P","volume":"14","author":"Bonham","year":"2008","journal-title":"ract"},{"key":"R4-2-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0891988703258658","article-title":"Psychosis in elderly patients: classification and pharmacotherapy.","volume":"16","author":"Mintzer","year":"2003","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.amjopharm.2008.10.002","article-title":"Antipsychotic drug use among elderly nursing home residents in the United States.","volume":"6","author":"Kamble","year":"2008","journal-title":"Am J Geriatr Pharmacother"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/pds.1600","article-title":"The use of central nervous system drugs and analgesics among very old people with and without dementia.","volume":"17","author":"Lovheim","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF03324781","article-title":"Use of antipsychotic medications in older home-care patients. Report from nine European countries.","volume":"20","author":"Alanen","year":"2008","journal-title":"Aging Clin Exp Res"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1185\/030079908X260989","article-title":"Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.","volume":"24","author":"Jano","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R9-2-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4088\/JCP.v69n0210","article-title":"Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.","volume":"69","author":"Taylor","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11096-007-9107-1","article-title":"The use of atypical antipsychotics in French psychiatric hospitals.","volume":"29","author":"Bret","year":"2007","journal-title":"Pharm World Sci"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/gps.1129","article-title":"Psychosocial correlates of late-onset psychosis: life experiences, cognitive schemas, and attitudes to ageing.","volume":"19","author":"Giblin","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1517\/14656566.9.14.2537","article-title":"Using risperidone for Alzheimers dementia-associated psychosis.","volume":"9","author":"McKneal","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R13-2-20210129","first-page":"279","article-title":"Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver Fam P","volume":"26","author":"Schoenmakers","year":"2009","journal-title":"ract"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4140\/TCP.n.2004.352","article-title":"Caregiver burden in Alzheimers disease.","volume":"19","author":"Slattum","year":"2004","journal-title":"Consult Pharm"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1017\/S1041610206003930","article-title":"Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care.","volume":"18","author":"Lovheim","year":"2006","journal-title":"Int Psychogeriatr"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1176\/ajp.155.11.1512","article-title":"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimers disease.","volume":"155","author":"Devanand","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R17-2-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.","volume":"53","author":"De Deyn","year":"1999","journal-title":"Neurology"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.","volume":"64","author":"Brodaty","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clineuro.2005.03.013","article-title":"Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.","volume":"107","author":"De Deyn","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.","volume":"14","author":"Mintzer","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00019442-200307000-00004","article-title":"Psychosis of Alzheimer disease: validity of the construct and response to risperidone.","volume":"11","author":"Schneider","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/gps.1792","article-title":"The efficacy and safety of risperidone in the treatment of psychosis of Alzheimers disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.","volume":"22","author":"Katz","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimers disease.","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","article-title":"Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.","volume":"14","author":"Tariot","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.","volume":"4","author":"Zhong","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.1032","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimers disease.","volume":"19","author":"De Deyn","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.","volume":"15","author":"Mintzer","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R31-2-20210129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.","volume":"16","author":"Streim","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"R32-2-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","article-title":"Aripiprazole for the treatment of psychosis in patients with Alzheimers disease: a randomized, placebo-controlled study.","volume":"25","author":"De Deyn","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R33-2-20210129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0033-3182(04)70170-X","article-title":"A double-blind trial of risperidone and haloperidol for the treatment of delirium.","volume":"45","author":"Han","year":"2004","journal-title":"Psychosomatics"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4088\/JCP.v65n0310","article-title":"Risperidone in the treatment of patients with delirium.","volume":"65","author":"Parellada","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R35-2-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-200304000-00002","article-title":"The efficacy and safety of olanzapine for the treatment of geriatric psychosis.","volume":"23","author":"Hwang","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v60n0109","article-title":"The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.","volume":"60","author":"Howanitz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/gps.1007","article-title":"Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.","volume":"18","author":"Kennedy","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00019442-200311000-00008","article-title":"International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.","volume":"11","author":"Jeste","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00019442-200002000-00004","article-title":"Psychosis of Alzheimers disease and related dementias. Diagnostic criteria for a distinct syndrome.","volume":"8","author":"Jeste","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.npp.1301492","article-title":"ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia.","volume":"33","author":"Jeste","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R41-2-20210129","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","article-title":"Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.","volume":"288","author":"Lyketsos","year":"2002","journal-title":"JAMA"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","article-title":"Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.","volume":"157","author":"Lyketsos","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"4","key":"R43-2-20210129","first-page":"CD002852","article-title":"Haloperidol for agitation in dementia.","author":"Lonergan","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"Theodoulou M, et al; DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/gps.504","article-title":"A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.","volume":"16","author":"Chan","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"R47-2-20210129","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4088\/JCP.v65n1217","article-title":"Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.","volume":"65","author":"Mulsant","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R48-2-20210129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.eurpsy.2007.03.001","article-title":"Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.","volume":"22","author":"Rainer","year":"2007","journal-title":"Eur Psychiatry"},{"key":"R49-2-20210129","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimers disease: randomised double blind placebo controlled trial.","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"key":"R50-2-20210129","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JGP.0b013e318167ae76","article-title":"The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homesa 12-month follow-up study.","volume":"16","author":"Selbaek","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"R52-2-20210129","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4088\/JCP.v69n0602","article-title":"Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.","volume":"69","author":"Salzman","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R53-2-20210129","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/gps.1617","article-title":"Differences in diagnostic subtypes among patients with late and early onset of a single depressive episode.","volume":"21","author":"Kessing","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"R54-2-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jad.2009.04.005","article-title":"The effectiveness of continuation-maintenance ECT in reducing depressed older patients hospital re-admissions.","volume":"120","author":"OConnor","year":"2010","journal-title":"J Affect Disord"},{"key":"R55-2-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0891988707311027","article-title":"Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature.","volume":"21","author":"Wilkins","year":"2008","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R56-2-20210129","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R57-2-20210129","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.07m03805","article-title":"Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.","volume":"70","author":"Sheffrin","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R58-2-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/(SICI)1099-1166(199905)14:5<379::AID-GPS924>3.0.CO;2-7","article-title":"Correlates of psychotic symptoms among elderly outpatients.","volume":"14","author":"Holroyd","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"R59-2-20210129","first-page":"CD005594","article-title":"Antipsychotics for delirium.","author":"Lonergan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R60-2-20210129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00023210-200822080-00002","article-title":"Delirium and its treatment.","volume":"22","author":"Attard","year":"2008","journal-title":"CNS Drugs"},{"key":"R61-2-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/schbul\/14.1.39","article-title":"Late-onset schizophrenia: an overview.","volume":"14","author":"Harris","year":"1988","journal-title":"Schizophr Bull"},{"key":"R62-2-20210129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1176\/appi.ajp.157.2.172","article-title":"Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group.","volume":"157","author":"Howard","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R63-2-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0920-9964(03)00015-X","article-title":"Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments.","volume":"67","author":"Sato","year":"2004","journal-title":"Schizophr Res"},{"key":"R64-2-20210129","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/JGP.0b013e31816c7b3c","article-title":"Clinical characterization of late- and very late-onset first psychotic episode in psychiatric inpatients.","volume":"16","author":"Girard","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"R65-2-20210129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hup.877","article-title":"Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.","volume":"22","author":"Kissling","year":"2007","journal-title":"Hum Psychopharmacol"},{"key":"R66-2-20210129","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1017\/S1041610208007606","article-title":"Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone.","volume":"20","author":"Tadger","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"R67-2-20210129","doi-asserted-by":"crossref","first-page":"a1227","DOI":"10.1136\/bmj.a1227","article-title":"Exposure to antipsychotics and risk of stroke: self controlled case series study.","volume":"337","author":"Douglas","year":"2008","journal-title":"BMJ"},{"key":"R69-2-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/157488606777934468","article-title":"The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly.","volume":"1","author":"Madhusoodanan","year":"2006","journal-title":"Curr Drug Saf"},{"key":"R70-2-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia.","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Intern Med"},{"key":"R71-2-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1503\/cmaj.050478","article-title":"Increased mortality among elderly patients with dementia using atypical antipsychotics.","volume":"173","author":"Singh","year":"2005","journal-title":"CMAJ"},{"key":"R73-2-20210129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1503\/cmaj.071540","article-title":"Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.","volume":"179","author":"Valiyeva","year":"2008","journal-title":"CMAJ"},{"key":"R74-2-20210129","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"R75-2-20210129","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications.","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"key":"R76-2-20210129","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archinte.165.6.696","article-title":"Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"key":"R77-2-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00019442-200407000-00012","article-title":"Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.","volume":"12","author":"Nasrallah","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"key":"R78-2-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4088\/JCP.v60n0504","article-title":"Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.","volume":"60","author":"McManus","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R79-2-20210129","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/j.1532-5415.2008.01839.x","article-title":"Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications.","volume":"56","author":"Setoguchi","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"R80-2-20210129","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/JCP.0b013e31815a882b","article-title":"Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.","volume":"27","author":"Wang","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R81-2-20210129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1503\/cmaj.1040539","article-title":"Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.","volume":"170","author":"Wooltorton","year":"2004","journal-title":"CMAJ"},{"key":"R82-2-20210129","first-page":"1269","article-title":"Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.","volume":"167","author":"Wooltorton","year":"2002","journal-title":"CMAJ"},{"key":"R84-2-20210129","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents.","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"key":"R85-2-20210129","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S1041610205002280","article-title":"Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.","volume":"17","author":"Finkel","year":"2005","journal-title":"Int Psychogeriatr"},{"key":"R86-2-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","article-title":"Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.","volume":"330","author":"Gill","year":"2005","journal-title":"BMJ"},{"key":"R87-2-20210129","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4088\/JCP.v66n0901","article-title":"Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.","volume":"66","author":"Liperoti","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R88-2-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0269881107080792","article-title":"Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects.","volume":"22","author":"Sacchetti","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R89-2-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0269881105056524","article-title":"Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.","volume":"19","author":"Layton","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R90-2-20210129","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/0269881108093583","article-title":"Risk of cerebrovascular events in elderly users of antipsychotics.","volume":"23","author":"Kleijer","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R91-2-20210129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JGP.0b13e318030253a","article-title":"Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients.","volume":"15","author":"Barak","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R92-2-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/JGP.0b013e31802d0b00","article-title":"Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study.","volume":"15","author":"Raivio","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R94-2-20210129","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/STROKEAHA.107.189063","article-title":"; American Heart Association; American Stroke Association. Update to the AHAASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.","volume":"39","author":"Adams","year":"2008","journal-title":"Stroke"},{"key":"R95-2-20210129","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bmj.314.7076.266","article-title":"Do neuroleptic drugs hasten cognitive decline in dementia Prospective study with necropsy follow up.","volume":"314","author":"McShane","year":"1997","journal-title":"BMJ"},{"key":"R96-2-20210129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/gps.1885","article-title":"Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.","volume":"23","author":"Deberdt","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"R97-2-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/14737175.7.4.423","article-title":"Neuroleptic malignant syndrome in elderly patients.","volume":"7","author":"Caroff","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"R98-2-20210129","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.encep.2007.11.007","article-title":"Neuroleptic malignant syndrome and atypical antipsychotics: a brief review.","volume":"34","author":"Khaldi","year":"2008","journal-title":"Encephale"},{"key":"R100-2-20210129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1345\/aph.1L066","article-title":"Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome.","volume":"42","author":"Stevens","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R101-2-20210129","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1017\/S1092852900021386","article-title":"Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.","volume":"12","author":"Kohen","year":"2007","journal-title":"CNS Spectr"},{"key":"R102-2-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"R103-2-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications.","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophr Res"},{"key":"R104-2-20210129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00002512-200522030-00006","article-title":"Atypical antipsychotics for nursing home patients: a retrospective chart review.","volume":"22","author":"Frenchman","year":"2005","journal-title":"Drugs Aging"},{"key":"R105-2-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1525-8610(04)70343-6","article-title":"Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.","volume":"4","author":"Martin","year":"2003","journal-title":"J Am Med Dir Assoc"},{"key":"R106-2-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.amjopharm.2007.09.003","article-title":"Olanzapine and acute urinary retention in two geriatric patients.","volume":"5","author":"Cohen","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"R107-2-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-200017050-00004","article-title":"Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations.","volume":"17","author":"Caligiuri","year":"2000","journal-title":"Drugs Aging"},{"key":"R108-2-20210129","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"R109-2-20210129","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1176\/ajp.155.11.1521","article-title":"Prospective study of tardive dyskinesia in the elderly: rates and risk factors.","volume":"155","author":"Woerner","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R110-2-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R111-2-20210129","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0006-3223(03)00170-7","article-title":"Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients.","volume":"53","author":"Dolder","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R112-2-20210129","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"R113-2-20210129","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1111\/j.1532-5415.2004.52604.x","article-title":"Optimizing atypical antipsychotic treatment strategies in the elderly.","volume":"52","author":"Katz","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"R114-2-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pcd.2008.10.005","article-title":"Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.","volume":"3","author":"Hasnain","year":"2009","journal-title":"Prim Care Diabetes"},{"key":"R115-2-20210129","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R116-2-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0891988706298629","article-title":"Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.","volume":"20","author":"Lipkovich","year":"2007","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R117-2-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1525-8610(04)70042-0","article-title":"Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.","volume":"5","author":"Feldman","year":"2004","journal-title":"J Am Med Dir Assoc"},{"key":"R118-2-20210129","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-4356(02)00588-7","article-title":"A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States.","volume":"56","author":"Buse","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"R119-2-20210129","doi-asserted-by":"crossref","first-page":"900","DOI":"10.4088\/JCP.v66n0713","article-title":"Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.","volume":"66","author":"Lamberti","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R120-2-20210129","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1345\/aph.1L015","article-title":"Antipsychotics and diabetes: an age-related association.","volume":"42","author":"Hammerman","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R121-2-20210129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndromea new world-wide definition. A consensus statement from the International Diabetes Federation.","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"R122-2-20210129","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"R123-2-20210129","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/ajp.2006.163.7.1273","article-title":"Prevalence of the metabolic syndrome among patients receiving clozapine.","volume":"163","author":"Lamberti","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R124-2-20210129","first-page":"596","article-title":"Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"R125-2-20210129","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00002512-200623120-00002","article-title":"Adverse effects of atypical antipsychotics in the elderly: a review.","volume":"23","author":"Gareri","year":"2006","journal-title":"Drugs Aging"},{"key":"R126-2-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.7.5.525","article-title":"The safety of clozapine in the elderly.","volume":"7","author":"Gareri","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"R127-2-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"key":"R128-2-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1176\/appi.psy.48.6.530","article-title":"Quetiapine-induced leucopenia and thrombocytopenia.","volume":"48","author":"Shankar","year":"2007","journal-title":"Psychosomatics"},{"key":"R129-2-20210129","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.pnpbp.2005.04.025","article-title":"Olanzapine-induced leucopenia and neutropenia.","volume":"29","author":"Stergiou","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R130-2-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.apnu.2006.04.004","article-title":"Outcomes of antipsychotic drug use in community-dwelling elders with dementia.","volume":"20","author":"Kolanowski","year":"2006","journal-title":"Arch Psychiatr Nurs"},{"key":"R131-2-20210129","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4088\/JCP.v68n0616","article-title":"Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study.","volume":"68","author":"Liperoti","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R132-2-20210129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1532-5415.2005.53403.x","article-title":"Atypical antipsychotic medications and risk of falls in residents of aged care facilities.","volume":"53","author":"Hien le TT, Cumming","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"R133-2-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1532-5415.2007.01625.x","article-title":"Antipsychotic drug use and risk of pneumonia in elderly people.","volume":"56","author":"Knol","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"R134-2-20210129","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/JCP.0b013e318184c905","article-title":"Antipsychotics and oropharyngeal dysphagia in hospitalized older patients.","volume":"28","author":"Rudolph","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R135-2-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold.","volume":"25","author":"Pisani","year":"2002","journal-title":"Drug Saf"},{"key":"R137-2-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0269881105048902","article-title":"A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care.","volume":"19","author":"Foster","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R139-2-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.eurpsy.2007.03.007","article-title":"Psychotropic drugs use and risk of heat-related hospitalisation.","volume":"22","author":"Martin-Latry","year":"2007","journal-title":"Eur Psychiatry"},{"key":"R140-2-20210129","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-007-0294-4","article-title":"Hypothermia following antipsychotic drug use.","volume":"63","author":"van Marum","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R141-2-20210129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1176\/appi.psy.43.5.354","article-title":"Cataract occurrence with antipsychotic drugs.","volume":"43","author":"Shahzad","year":"2002","journal-title":"Psychosomatics"},{"key":"R142-2-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2006.04.005","article-title":"Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.","volume":"86","author":"Byerly","year":"2006","journal-title":"Schizophr Res"},{"key":"R143-2-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1533317507300514","article-title":"The Closing Group: therapeutic recreation for nursing home residents with dementia and accompanying agitation andor anxiety.","volume":"22","author":"Putman","year":"2007","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"R144-2-20210129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002512-200825050-00003","article-title":"Alternatives to atypical antipsychotics for the management of dementia-related agitation.","volume":"25","author":"Passmore","year":"2008","journal-title":"Drugs Aging"},{"key":"R146-2-20210129","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JGP.0b013e3181b0f8c0","article-title":"Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).","volume":"17","author":"Ballard","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"R147-2-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00019442-200111000-00005","article-title":"Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique.","volume":"9","author":"Cohen-Mansfield","year":"2001","journal-title":"Am J Geriatr Psychiatry"},{"key":"R148-2-20210129","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.","volume":"15","author":"Pollock","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R149-2-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/10673220903129798","article-title":"The use of selective serotonin reuptake inhibitors in elderly patients.","volume":"17","author":"Chemali","year":"2009","journal-title":"Harv Rev Psychiatry"},{"key":"R150-2-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitationaggression and psychosis in moderately severe to severe Alzheimers disease: a pooled analysis of 3 studies.","volume":"69","author":"Wilcock","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R151-2-20210129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"R152-2-20210129","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimers disease.","volume":"357","author":"Howard","year":"2007","journal-title":"N Engl J Med"},{"key":"R153-2-20210129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000094975","article-title":"Treatment of delusions in Alzheimers diseaseresponse to pharmacotherapy.","volume":"22","author":"Fischer","year":"2006","journal-title":"Dement Geriatr Cogn Disord"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00023727-201004000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:15:09Z","timestamp":1786040109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00023727-201004000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":144,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.3109\/10673221003747690","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}